COMORBIDITY AND ITS IMPACT ON THE COURSE OF GOUT AND COVID-19

S. Smiyan, O. Makhovska
{"title":"COMORBIDITY AND ITS IMPACT ON THE COURSE OF GOUT AND COVID-19","authors":"S. Smiyan, O. Makhovska","doi":"10.25040/ntsh2022.01.14","DOIUrl":null,"url":null,"abstract":"Introduction. Comorbid diseases signifi cantly exacerbate gout burden, represent an even more elevated risk of hospitalization and mortality rates owing to the coronavirus disease 2019 (COVID-19) than gout itself. Objectives. To evaluate the infl uence of the modifi ed Rheumatic Disease Comorbidity Index (mRDCI) on the clinical course of gout and COVID-19. Methods. Using data from 136 male participants with gout, we distributed the cohort according to values of the mRDCI as follows: 0 – without comorbidities, 1-2 – low comorbidity index (CI), 3-4 – moderate CI and ≥5 – high CI. “Treat-to-target” approach for gout, the association of mRDCI with the clinical course of gout, lipid metabolism, and severity of COVID-19 were analyzed. Results. According to mRDCI scores, almost every second gout patient (45.6%) had moderate CI, every fi fth (19.1%) – high CI, and 14.7% – low CI. Greater mRDCI was associated with the higher severity of COVID-19 (p=0.003), limited physical functioning (r=0.5, p<0.001), higher body mass index (r=0.63, p<0.001), hyperuricemia (r=0.37, p<0.001), increased low–density lipoprotein cholesterol (LDL–C) (r=0.38, p<0.001), higher gout activity (r=0.4, p<0.001), more frequent acute fl ares in the preceding year (r=0.39, p<0.001), number of tophi (r=0.31, p<0.001), longer duration of gout (r=0.34, p<0.001), reduced glomerular fi ltration rate (r =–0.39, p<0.001), and daily excretion of uric acid (UA) (r=–0.28, p=0.001). The target level of serum UA was achieved in 22.1%. The majority of patients were not controlled for LDL-C (83.7%), blood pressure (75.5%), and glucose (69.44%) in the cohort with dyslipidemia, hypertension, and diabetes respectively. Conclusion. The high prevalence of comorbidities in gout patients was associated with the severity of COVID-19. We have established the following three patterns of comorbidity predictors: anthropometric, disease-related, and dysmetabolic. The management of gout requires a multidisciplinary approach.","PeriodicalId":140699,"journal":{"name":"Proceedings of the Shevchenko Scientific Society. Medical Sciences","volume":"2017 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the Shevchenko Scientific Society. Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25040/ntsh2022.01.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction. Comorbid diseases signifi cantly exacerbate gout burden, represent an even more elevated risk of hospitalization and mortality rates owing to the coronavirus disease 2019 (COVID-19) than gout itself. Objectives. To evaluate the infl uence of the modifi ed Rheumatic Disease Comorbidity Index (mRDCI) on the clinical course of gout and COVID-19. Methods. Using data from 136 male participants with gout, we distributed the cohort according to values of the mRDCI as follows: 0 – without comorbidities, 1-2 – low comorbidity index (CI), 3-4 – moderate CI and ≥5 – high CI. “Treat-to-target” approach for gout, the association of mRDCI with the clinical course of gout, lipid metabolism, and severity of COVID-19 were analyzed. Results. According to mRDCI scores, almost every second gout patient (45.6%) had moderate CI, every fi fth (19.1%) – high CI, and 14.7% – low CI. Greater mRDCI was associated with the higher severity of COVID-19 (p=0.003), limited physical functioning (r=0.5, p<0.001), higher body mass index (r=0.63, p<0.001), hyperuricemia (r=0.37, p<0.001), increased low–density lipoprotein cholesterol (LDL–C) (r=0.38, p<0.001), higher gout activity (r=0.4, p<0.001), more frequent acute fl ares in the preceding year (r=0.39, p<0.001), number of tophi (r=0.31, p<0.001), longer duration of gout (r=0.34, p<0.001), reduced glomerular fi ltration rate (r =–0.39, p<0.001), and daily excretion of uric acid (UA) (r=–0.28, p=0.001). The target level of serum UA was achieved in 22.1%. The majority of patients were not controlled for LDL-C (83.7%), blood pressure (75.5%), and glucose (69.44%) in the cohort with dyslipidemia, hypertension, and diabetes respectively. Conclusion. The high prevalence of comorbidities in gout patients was associated with the severity of COVID-19. We have established the following three patterns of comorbidity predictors: anthropometric, disease-related, and dysmetabolic. The management of gout requires a multidisciplinary approach.
合并症及其对痛风和COVID-19病程的影响
介绍。合并症显著加重了痛风负担,与痛风本身相比,2019冠状病毒病(COVID-19)导致的住院和死亡率风险更高。目标。评价改良的风湿病共病指数(mRDCI)对痛风和COVID-19临床病程的影响。方法。使用来自136名男性痛风患者的数据,我们根据mRDCI的值将队列分配如下:0 -无合并症,1-2 -低合并症指数(CI), 3-4 -中度CI和≥5 -高CI。分析痛风“从治疗到靶向”方法、mRDCI与痛风临床病程、脂质代谢和COVID-19严重程度的关系。结果。根据mRDCI评分,几乎每2个痛风患者(45.6%)有中度CI,每5个患者(19.1%)有高CI, 14.7%有低CI。较高的mRDCI与较高的COVID-19严重程度(p=0.003)、身体功能受限(r=0.5, p<0.001)、较高的体重指数(r=0.63, p<0.001)、高尿酸血症(r=0.37, p<0.001)、低密度脂蛋白胆固醇(LDL-C)升高(r=0.38, p<0.001)、较高的痛风活动(r=0.4, p<0.001)、前一年更频繁的急性急性发作(r=0.39, p<0.001)、痛风数量(r=0.31, p<0.001)、更长的痛风持续时间(r=0.34, p<0.001)相关。降低肾小球滤过率(r= -0.39, p<0.001)和尿酸(UA)日排泄量(r= -0.28, p=0.001)。血清UA达标率为22.1%。在血脂异常、高血压和糖尿病队列中,大多数患者未控制LDL-C(83.7%)、血压(75.5%)和血糖(69.44%)。结论。痛风患者合并症的高患病率与COVID-19的严重程度相关。我们已经建立了以下三种模式的合并症预测:人体测量,疾病相关和代谢障碍。痛风的管理需要多学科的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信